These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 9460549)

  • 1. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions.
    Lewis MR; Shively JE
    Bioconjug Chem; 1998; 9(1):72-86. PubMed ID: 9460549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
    Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
    Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
    Lewis MR; Raubitschek A; Shively JE
    Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions.
    Li L; Tsai SW; Anderson AL; Keire DA; Raubitschek AA; Shively JE
    Bioconjug Chem; 2002; 13(1):110-5. PubMed ID: 11792185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL; DeNardo SJ; DeNardo GL; O'Donnell RT; Meares CF
    J Nucl Med; 1998 Dec; 39(12):2105-10. PubMed ID: 9867151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA.
    Lewis MR; Kao JY; Anderson AL; Shively JE; Raubitschek A
    Bioconjug Chem; 2001; 12(2):320-4. PubMed ID: 11312695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
    Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.
    Li M; Meares CF; Zhong GR; Miers L; Xiong CY; DeNardo SJ
    Bioconjug Chem; 1994; 5(2):101-4. PubMed ID: 8031871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies.
    Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Nilsson R; Sandberg BE; Brechbiel M
    Bioconjug Chem; 2002; 13(5):1079-92. PubMed ID: 12236790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
    Li M; Meares CF; Salako Q; Kukis DL; Zhong GR; Miers L; DeNardo SJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5726s-5728s. PubMed ID: 7493335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
    Lu SX; Takach EJ; Solomon M; Zhu Q; Law SJ; Hsieh FY
    J Pharm Sci; 2005 Apr; 94(4):788-97. PubMed ID: 15729708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
    DeNardo SJ; Zhong GR; Salako Q; Li M; DeNardo GL; Meares CF
    J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides.
    Xu LC; Nakayama M; Harada K; Kuniyasu A; Nakayama H; Tomiguchi S; Kojima A; Takahashi M; Ono M; Arano Y; Saji H; Yao Z; Sakahara H; Konishi J; Imagawa Y
    Bioconjug Chem; 1999; 10(1):9-17. PubMed ID: 9893958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.
    Deshpande SV; DeNardo SJ; Kukis DL; Moi MK; McCall MJ; DeNardo GL; Meares CF
    J Nucl Med; 1990 Apr; 31(4):473-9. PubMed ID: 2324823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosynthesis of new [90Y]-DOTA-based maleimide reagents suitable for the prelabeling of thiol-bearing L-oligonucleotides and peptides.
    Schlesinger J; Fischer C; Koezle I; Vonhoff S; Klussmann S; Bergmann R; Pietzsch HJ; Steinbach J
    Bioconjug Chem; 2009 Jul; 20(7):1340-8. PubMed ID: 19552458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
    DeNardo SJ; DeNardo GL; Yuan A; Richman CM; O'Donnell RT; Lara PN; Kukis DL; Natarajan A; Lamborn KR; Jacobs F; Siantar CL
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.
    Junghans RP; Dobbs D; Brechbiel MW; Mirzadeh S; Raubitschek AA; Gansow OA; Waldmann TA
    Cancer Res; 1993 Dec; 53(23):5683-9. PubMed ID: 8242624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and quantification of free sulfhydryls in monoclonal antibodies using maleimide labeling and mass spectrometry.
    Robotham AC; Kelly JF
    MAbs; 2019; 11(4):757-766. PubMed ID: 30894096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrocyclic chelates of radiometals for diagnosis and therapy.
    Meares CF; Moi MK; Diril H; Kukis DL; McCall MJ; Deshpande SV; DeNardo SJ; Snook D; Epenetos AA
    Br J Cancer Suppl; 1990 Jul; 10():21-6. PubMed ID: 2383477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.
    Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N
    J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.